IL1B and myeloid sarcoma: MS is typically associated with systemic low-grade inflammation, which is characterized by activation of certain pro-inflammatory signaling pathways and increased levels of pro-inflammatory cytokines, such as LPS, IL-1β, IL-6, and TNF-α33.